A population-based serological survey of *Vibrio cholerae* antibody titers in Ouest Department, Haiti in the year prior to the 2022 cholera outbreak

Authors:

Christy H. Clutter^{1,2,#}, Molly B. Klarman^{3,#}, Youseline Cajusma³, Emilie T. Cato³, Md. Abu Sayeed³, Lindsey Brinkley³, Owen Jensen², Chantale Baril⁴, V. Madsen Beau De Rochars⁵, Andrew S. Azman⁶, Maureen T. Long^{7,8}, Derek Cummings^{7,8}, Daniel T. Leung^{1,2,*}, Eric J. Nelson^{7,8*}

¹Division of Infectious Disease, University of Utah, Salt Lake City, Utah, USA

²Division of Microbiology & Immunology, University of Utah, Salt Lake City, Utah, USA

- ³University of Florida, Departments of Pediatrics and Environmental and Global Health, Gainesville, Florida, USA
- ⁴Université d'État d'Haïti (UEH), Port au Prince, Haiti
- ⁵Department of Health Services Research, Management and Policy, School of Public Health and Health Professions, University of Florida, Gainesville, Florida, USA
- ⁶Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
- ⁷Department of Comparative Diagnostic and Population Medicine, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA
- ⁸University of Florida, Emerging Pathogens Institute, Gainesville, Florida, USA

[#]These first authors contributed equally to this article *These senior authors contributed equally to this article

Corresponding author:

Christy H. Clutter. Division of Microbiology and Immunology, University of Utah. Salt Lake City, Utah, USA Email: christy.clutter@hsc.utah.edu

Key words: Cholera, Haiti, Outbreak, Serosurvey, ELISA, Vibriocidal, Correlates of Protection, Dried Blood Spots

1 ABSTRACT

2	After three years with no confirmed cholera cases in Haiti, an outbreak of Vibrio cholerae O1
3	emerged in October 2022. Levels of pre-existing antibodies provide an estimate of prior
4	immunologic exposure, reveal potentially relevant immune responses, and set a baseline for
5	future serosurveillance. We analyzed dried blood spots collected in 2021 from a population-
6	weighted representative cross-sectional serosurvey in two communes in the Ouest Department of
7	Haiti. We found lower levels of circulating IgG and IgA antibodies against V. cholerae
8	lipopolysaccharide (LPS, IgG and IgA p<0.0001) in those below 5 years of age compared to
9	those five years and older. Among a subset of patients with higher titers of antibodies, we were
10	unable to detect any functional (vibriocidal) antibodies. In conclusion, the lack of detectable
11	functional antibodies, and age-discordant levels of V. cholerae LPS IgG, suggest that populations
12	in Haiti may be highly susceptible to cholera disease, especially among young children.

13 INTRODUCTION

14 In October 2010, the UN peacekeeping mission accidentally introduced cholera into post-15 earthquake Haiti (1–6). Over the next nine years, approximately 820,000 cholera cases and 16 10,000 deaths were recorded (7). A response was ultimately organized through a national 17 elimination plan (8), and the last confirmed case of cholera was reported in late January of 2019 18 (9). In February of 2022, following a 3-year period with no confirmed cases, the Haitian Ministry 19 of Health was optimistic that cholera elimination had been achieved (10). Unfortunately, 10 20 months later, in a period of instability that compromised access to clean water and sanitation, two cases of cholera were confirmed on October 2nd of 2022 and a new outbreak started, which 21 22 as of January 31, 2023, had led to more than 27,000 suspected cases and 560 registered deaths 23 (11).

24 Phylogenetic analyses suggested the current strain was a descendent of the Vibrio 25 cholerae O1 Ogawa strain responsible for the original outbreak (12,13). Combatting this new 26 outbreak is challenged by security and humanitarian crises (14,15); however, legacy knowledge 27 and infrastructure remain from the previous outbreak (16,17). There may also be protective 28 immunity afforded by prior infection or vaccination. In the absence of ongoing transmission, 29 younger populations not present in the prior outbreak period would be immunologically naïve 30 and at higher risk of infection. This hypothesis is supported by a report of high rates of young 31 children presenting with cholera (18).

Upon exposure to toxigenic *V. cholerae*, the adaptive antibody response is dominated by two epitopes: cholera toxin and lipopolysaccharide (LPS) (19). However, the most clearly defined non-mechanistic correlate of protection for cholera is the presence of vibriocidal antibodies. These antibodies are functional bactericidal antibodies that target the O-specific

36	antigen of the V. cholerae LPS (20-22). Circulating antibody titers peak within several weeks			
37	post-infection and slowly wane to baseline over the ensuing months to years, with high levels of			
38	inter-individual variability (21). Killed whole-cell oral cholera vaccines (OCVs), such as those			
39	distributed in the Haiti vaccine campaigns conducted in Haiti, are on average 58% effective for			
40	the first two years, declining to 26% by four years post-vaccination (23). Children under five			
41	years of age show approximately half the level of protection by OCV at 2-year follow-up relative			
42	to adults (24).			
43	Given that natural infections were not reported, nor vaccinations administered in the three			
44	years prior to the 2022 outbreak, we investigated the presence of V. cholerae-specific antibodies			
45	in adults and children by analyzing samples collected in a cross-sectional serological survey in			
46	two communes in the Ouest Department of Haiti conducted prior to the 2022 outbreak.			
47	METHODS			
47 48	METHODS Ethics statement. The study was reviewed and approved by the Comité National de Bioéthique			
47 48 49	METHODS Ethics statement. The study was reviewed and approved by the Comité National de Bioéthique (National Bioethics Committee of Haiti; 2021-12), the Institutional Review Boards at University			
47 48 49 50	METHODS Ethics statement. The study was reviewed and approved by the Comité National de Bioéthique (National Bioethics Committee of Haiti; 2021-12), the Institutional Review Boards at University of Florida (IRB202002290), and the University of Utah (IRB_00111137).			
47 48 49 50 51	METHODS Ethics statement. The study was reviewed and approved by the Comité National de Bioéthique (National Bioethics Committee of Haiti; 2021-12), the Institutional Review Boards at University of Florida (IRB202002290), and the University of Utah (IRB_00111137). Study design. Cross-sectional serological survey.			
47 48 49 50 51 52	METHODSEthics statement. The study was reviewed and approved by the Comité National de Bioéthique(National Bioethics Committee of Haiti; 2021-12), the Institutional Review Boards at Universityof Florida (IRB202002290), and the University of Utah (IRB_00111137).Study design. Cross-sectional serological survey.Study population and setting. This study was conducted from February 24 th to August 25 th ,			
 47 48 49 50 51 52 53 	METHODSEthics statement. The study was reviewed and approved by the Comité National de Bioéthique(National Bioethics Committee of Haiti; 2021-12), the Institutional Review Boards at Universityof Florida (IRB202002290), and the University of Utah (IRB_00111137).Study design. Cross-sectional serological survey.Study population and setting. This study was conducted from February 24 th to August 25 th ,2021, in the communes of Gressier and Leogane, in the Ouest Department of Haiti. This semi-			
 47 48 49 50 51 52 53 54 	METHODS Ethics statement. The study was reviewed and approved by the Comité National de Bioéthique (National Bioethics Committee of Haiti; 2021-12), the Institutional Review Boards at University of Florida (IRB202002290), and the University of Utah (IRB_00111137). Study design. Cross-sectional serological survey. Study population and setting. This study was conducted from February 24 th to August 25 th , 2021, in the communes of Gressier and Leogane, in the Ouest Department of Haiti. This semi- urban and rural region experienced a cumulative attack rate of 5.1-7.5% (25) early in the original			
 47 48 49 50 51 52 53 54 55 	METHODS Ethics statement. The study was reviewed and approved by the Comité National de Bioéthique (National Bioethics Committee of Haiti; 2021-12), the Institutional Review Boards at University of Florida (IRB202002290), and the University of Utah (IRB_00111137). Study design. Cross-sectional serological survey. Study population and setting. This study was conducted from February 24 th to August 25 th , 2021, in the communes of Gressier and Leogane, in the Ouest Department of Haiti. This semi- urban and rural region experienced a cumulative attack rate of 5.1-7.5% (25) early in the original cholera outbreak (2010-2012). Cases decreased substantially over time so that towards the end of			
 47 48 49 50 51 52 53 54 55 56 	METHODS Ethics statement. The study was reviewed and approved by the Comité National de Bioéthique (National Bioethics Committee of Haiti; 2021-12), the Institutional Review Boards at University of Florida (IRB202002290), and the University of Utah (IRB_00111137). Study design. Cross-sectional serological survey. Study population and setting. This study was conducted from February 24 th to August 25 th , 2021, in the communes of Gressier and Leogane, in the Ouest Department of Haiti. This semi- urban and rural region experienced a cumulative attack rate of 5.1-7.5% (25) early in the original cholera outbreak (2010-2012). Cases decreased substantially over time so that towards the end of the outbreak the entirety of the Ouest Department reported 841 cases in 2018 (26). This region			

58 Sampling and randomization. Households were randomly sampled geographically and 59 proportionally to population density across the 477 sq km study area. A sampling grid was 60 constructed inside the study area with 149 total grid cells using ArcGIS (ESRI). Grid cells were 61 stratified by population density (low 0-399, medium 400-1511, high 1512-4664) and the sample 62 schema was established a priori. Twenty-five grid cells were randomly chosen proportional to 63 population density (2 low, 5 medium, 18 high). An additional 6 low density grid cells were 64 added to have statistical power to conduct future stratified analyses on population density effects. 65 Logistical constraints resulted in 25 grid-cells sampled (6 low, 3 medium, 15 high) out of the 31 66 intended to be sampled. Within each grid cell sampled, 21 points were randomly distributed and 67 enclosed by Thiessen polygons. Within each polygon, one household was enrolled and sampled; 68 the intention was to enroll from 18 of the 21 polygons per selected grid cell; the remaining 3 69 were used as 'back-up' polygons. The order that grid cells were sampled was randomized. 70 Participant recruitment. Haitian staff navigated to each grid cell and polygon (via car, 71 motorcycle, or foot) using ArcGIS Collector (ESRI). The first household reached upon entering 72 the targeted polygon was screened. If the household declined participation or was ineligible, 73 screening continued by proceeding to the next closest house, while remaining within the 74 polygon. A 'spin the bottle' app was used to determine the 'closest' house if there were multiple 75 equidistant neighboring houses. This process was repeated until either one household was 76 enrolled per polygon (18 total per grid cell) or all households within the polygon were screened. 77 Participant inclusion criteria, consent process, and incentives. Eligibility criteria included a 78 household with one adult head of household (HoH) who provided written consent to complete a 79 household survey and at least two household members who provided written consent to provide a 80 dried blood spot (DBS) sample and respond to a household member survey. Parents/guardians 18

81 years and older provided consent for their minor children and children ≥ 7 years provided assent. 82 Households with a single member were eligible if both consent for the surveys and DBS sample 83 were provided. There was no lower age limit for eligibility. A 500 Gourde (\$4.50 US) phone 84 credit was provided to HoH participants to facilitate contact with the study hotline for questions. 85 **Sample collection.** DBS sampling was performed by finger stick, or heel stick in children <1 86 year, and spotted onto Whatman 903 Protein Saver cards. 87 **Data collection.** The HoH survey queried family demographics and socioeconomic status. The 88 household member survey asked about current and past symptoms and history relating to 89 diarrheal syndromes. Vaccination and disease history were self-reported. Children under 5 years 90 were measured for basic parameters of malnutrition (mid-upper arm circumference (MUAC), 91 weight, and height).

92 **DBS Eluates.** Using a hole puncher, nine 6mm spots were punched from the blood circles on

93 each DBS card and placed into a microcentrifuge tube containing 600 μ L of a 1X PBS-Tween

solution. The samples were then placed on a tube rocker at speed 50 rpm overnight at 4°C. The

95 next day the samples were centrifuged at 10,500 x g for 2 minutes. The supernatant was removed

96 and stored at -80°C until ready for further use.

97 ELISA. Enzyme-linked immunosorbent assays (ELISAs) were performed on all DBS specimens

98 (n=861). Nunc Maxisorp flat-bottom plates (Sigma-Aldrich) were coated overnight with either V.

99 cholerae O1 Ogawa-specific LPS (gift of Edward Ryan, Massachusetts General Hospital) or

100 monosialoganglioside (GM₁, Sigma-Aldrich) at $1 \mu g/mL$. Plates that had been coated with GM₁

101 were washed in phosphate buffered saline (PBS) with 0.05% Tween20 (PBST), blocked in PBST

102 + 1% bovine serum albumin (BSA), and coated for a second night in cholera toxin subunit B

103 (CtxB, Sigma-Aldrich) at 2.5 µg/mL. Following coating, plates were blocked, incubated with

104 DBS eluates that were diluted 1:7.5 in PBST + 0.1% BSA, incubated in 1:1000 horseradish 105 peroxidase (HRP) conjugated secondary antibody, either goat-anti-human IgG or IgA (Jackson 106 ImmunoResearch), and developed in TMB substrate solution (Thermo Scientific). Immediately 107 after addition of TMB, plates were placed on a BioTek ELx800 plate reader and read kinetically 108 at 405nm once every minute for eight minutes. Maximum slope (MaxV) values were normalized 109 against a positive control for each plate to generate ELISA units. Positive controls were 110 convalescent plasma from confirmed cholera cases, diluted 1:100. Negative controls were naïve 111 serum (Sigma-Aldrich), also diluted 1:100. 112 Vibriocidal antibody assay. The criteria to select samples for vibriocidal antibody assays were 113 those samples with an IgG ELISA titer two standard deviations above the mean for either LPS 114 IgG or CtxB IgG. The assay was conducted via a previously described DBS eluate-adapted drop-115 plate vibriocidal method (30) and adapted for this study. V. cholerae O1 El Tor Ogawa strain 116 (X25049) were grown overnight on thiosulfate-citrate-bile salts-sucrose (TCBS) Vibrio-selective 117 agar, after which 2-3 colonies were cultured in Luria-Betani (LB) broth, washed several times 118 with sterile PBS and adjusted to an OD_{600} of 0.3. DBS samples were diluted 1:5 in sterile PBS, 119 heat-inactivated at 56°C, and then serially diluted 1:2 horizontally across a flat-bottom 120 NunclonTM Delta Surface 96-well plate (Thermo Scientific). Each 96-well-plate included three 121 growth controls and three negative controls. Each batch included at least one monoclonal 122 antibody positive control. Samples and positive controls were cultured for 1hr in a growth 123 solution containing the normalized V. cholerae culture ($OD_{600} = 0.3$) and guinea pig complement 124 (Sigma-Aldrich). Negative controls were cultured with sterile PBS. Plate controls were 125 subsequently plated in 5µL drops onto LB agar. Positive control and participant samples were 126 plated onto TCBS agar (selective media for V. cholerae) and cultured overnight at 37°C. Titers

were determined as the reciprocal of the first dilution in which the culture drop shows serratededges or individual colonies.

129 Statistical Analyses. Statistical comparisons between two populations were assessed with an

130 unpaired, two-tailed Student's t test. Significance was determined at p≤0.05. Generalized

131 additive models (GAMs) with a spline to fit age were used to assess the relationship of age and

132 antibody distribution. R version 4.1.3 with the mgcv package was used to fit the splines.

133 **RESULTS**

134 In this cross-sectional serological survey, we collected DBS samples from 861 enrolled

adult (n=564) and child (<18 years, n=297) participants (Table 1); 62.6% were female. A small

136 percentage of participants self-reported prior cholera vaccination (n=10/861, 1.2%) or self-

137 reported clinical disease (n=37/861, 4.3%).

138 Antibody titers for V. cholerae LPS and CtxB were measured across the population for 139 both IgG and IgA isotypes (Figure 1A). Children less than 5 years old had significantly lower 140 titers of both LPS IgG and IgA (p<0.0001, Figure 2A-B, Supplemental Table 1) compared to 141 children and adults 5 and older. CtxB IgG was elevated in children under 5 (p=0.0033), 142 specifically within 1-2-year-old children (p=0.0024 and p=0.0011 respectively, Figure 2C). 143 There was a significant difference between children under 5, older children, and adults with 144 respect to CtxB IgA, but this was driven by the youngest children under 1 year of age, who may 145 lack antibody for reasons unrelated to exposure (Figure 2D). Medians, p-values and interquartile 146 ranges are presented in Supplemental Table 1. Using generalized additive model (GAM) based 147 splines, we estimated a significant positive non-linear association of IgA isotypes with age (LPS: 148 effective degrees of freedom (EDF) 3.4, p<2e-16; CtxB: EDF 2.0, p<e-16) (Supplemental Figure

149 1). This association was not significant for IgG isotypes (LPS: EDF 4.9, p=0.12; CtxB: EDF 1.0,
150 p=0.13).

151 Vibriocidal assays were conducted on the subset of participant samples (n=51/861, 5.9%)
152 that had IgG titers for either LPS or CtxB at two standard deviations above the mean. No
153 samples tested had detectable vibriocidal responses (Figure 1B).

154 **DISCUSSION**

155 In this cross-sectional serological survey in a regional population within Haiti, we 156 detected low rates of circulating IgG and IgA antibodies against lipopolysaccharide (LPS) and 157 cholera toxin subunit B (CtxB). Within the context of increasing antibody response with age, 158 children 1-4 years of age had lower antibody titers against LPS IgG and LPS IgA compared to 159 adults and children over five. Children 1-2 years old had elevated titers of CtxB IgG, which may 160 reflect the cross-reactive nature of CtxB antibodies with the heat-labile toxin (LT) of 161 enterotoxigenic *Escherichia coli*, which has the highest force of infection (measured by 162 seroconversion rate per child-year) among enteric pathogens in Haitian children (31). Due to the 163 inherent cross-reactivity of CtxB, LPS IgG is more specific for exposure history to V. cholerae 164 and IgG is more meaningful for age-related comparisons. However, no functional (vibriocidal) 165 antibodies, which is the best available correlate of protection for cholera, were detected.

166 The serologic assays used in our study have been demonstrated to be associated with 167 prior infection with *V. cholerae* O1 based on longitudinal studies of culture-confirmed cholera 168 patients (21), and also demonstrated to be associated with protection against disease in studies of 169 household contacts of index cases and in human challenge studies (21,32,33). Our data are 170 consistent with limited recent disease transmission and antigenic exposure in this community,

especially among young children that were born in the period with little to no circulating
pandemic *V. cholerae*. These serologic data suggest that the Haitian communities surveyed may
have limited pre-existing immunologic protection against cholera, especially among children
under 5 years of age.

The 2022 outbreak was caused by a *V. cholerae* Ogawa isolate that aligns with isolates circulating during the 2010-2019 outbreak (12,13). In the period between outbreaks, the degree to which *V. cholerae* circulated in human and environmental reservoirs at a level below the threshold detectable by the surveillance infrastructure is unknown. The intersection between low levels of circulating cholera and declining population immunity were likely important factors that put Haiti at risk of this new outbreak. These factors, combined with the collapse of clean water and sanitation infrastructure, likely catalyzed the 2022 outbreak.

182 The findings in this study must be considered within the context of the study limitations. 183 First, there was a risk of enrollment bias because only 28% of the households screened consented 184 to participate, which is lower than other studies in the area that employed similar recruitment 185 methods (34); given oversampling among low density grid cells, the 'true' distribution across the 186 population would need adjustment if these data are used as a baseline for future serosurveillance 187 research. Second, the observations of lower IgA antibody titers in children 1-4 may be part of a 188 larger trend of increasing IgA antibody responses with age, representing a confounding factor, 189 and thus may not reflect specific exposures as hypothesized. Third, The ELISA was limited by 190 the availability of quantitative and matrix-matched controls, leading to the use of convalescent 191 plasma as a positive control, and naïve serum as a negative control. Fourth, the selection of 192 samples with high ELISA units for vibriocidal assays may have missed samples with lower 193 antibody levels but harboring functional antibodies. It is possible that matrix differences between

- 194 DBS and serum/plasma may have impacted the analysis. Finally, our serosurvey was limited to
- 195 two adjacent communes in the Ouest Department of Haiti, and our findings may not be
- 196 generalizable to other locations in the country.

197 CONCLUSION

- 198 In conclusion, our population-based serosurvey of two Haitian communities revealed a
- 199 lack of functional antibodies, and significantly lower V. cholerae LPS-specific IgG antibodies
- 200 among young children. Our findings suggest that populations in Haiti may be highly susceptible
- 201 to cholera disease and outbreaks, especially among young children.

203 Acknowledgements

- 204 We are grateful to the participants as well as the team who conducted the survey in Haiti. We
- 205 would like to thank the administrators and leadership at the Emerging Pathogens Institute and the
- 206 Department of Pediatrics at the University of Florida for their ongoing support. We also honor
- 207 the dedication and support of the Ministry of Public Health and Population (Ministère de la Santé
- 208 Publique et de la Population MSPP) for their commitment to the health of the Haitian
- 209 population despite the profound period of instability.
- 210 **Conflict of Interest Disclosures.** The authors declare that they have no competing interests.
- 211 Funding. Funding for this study was provided through grant support to DTL from the National
- 212 Institute of Allergy and Infectious Diseases (R01 AI135115) and EJN from the Children Miracle
- 213 Network (Florida).
- 214 Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study;
- 215 collection, management, analysis, and interpretation of the data; preparation, review, or approval
- 216 of the manuscript; and decision to submit the manuscript for publication.

217 Abbreviations and Acronyms

- 218 LPS Lipopolysaccharide
- 219 CtxB Cholera toxin subunit B
- 220 DBS Dried blood spot
- 221 ELISA Enzyme-linked immunosorbent assay
- 222 IgG, IgA Immunoglobulin G, Immunoglobulin A

223 Table 1. Participant Characteristics

224

Characteristic	Number (n)	Percentage of Total
Total Participants	861	100
Sex		
Male	322	37.4%
Female	539	62.6%
Age		
Adult ≥18	564	65.5%
Children <18	297	34.5%
Children <5	112	13%
Cholera Vaccination Status		
Vaccinated	10	1.2%
Not Vaccinated	847	98.4%
Unsure	4	0.4%
Prior Infection		
Yes	37	4.3%
No	822	95.5%
Unsure	2	0.2%

225

FIGURE 1



228

Figure 1. *Vibrio cholerae* specific and functional antibodies. Enzyme-linked immunosorbent

assays (ELISAs) were performed on all 861 samples for LPS and CtxB, for both IgG and IgA
 serotypes (A). Samples that were two standard deviations above the mean for LPS or CtxB IgG

(n=51) were assayed for functional (vibriocidal) antibodies (B). Abbreviations: LPS =

233 lipopolysaccharide; CtxB = cholera toxin subunit B. Median and interquartile ranges are

- displayed (A).
- 235

236 FIGURE 2



237

238

239 Figure 2. Antibody titers by age, vaccination status, and prior infection. Antibody titers for

240 LPS and CtxB were compared between children under 5 years old (n=112) and adults and

children five and older for LPS IgG (A), LPS IgA (B), CtxB IgG (C) and CtxB IgA. Statistical

242 comparisons between ≥ 5 and < 5 were made using an unpaired two-tailed student's t test.

243 Individual year-by-year comparisons were compared by one-way ANOVA. Significance is

244 annotated as follows: $*p \le 0.05$, $**p \le 0.01$ $***p \le 0.001$ $***p \le 0.0001$.

245 **REFERENCES**

- Lantagne D, Balakrish Nair G, Lanata CF, Cravioto A. The Cholera Outbreak in Haiti: Where
 and How did it begin? In: Nair GB, Takeda Y, editors. Cholera Outbreaks [Internet]. Berlin,
 Heidelberg: Springer; 2014 [cited 2022 Dec 16]. p. 145–64. (Current Topics in Microbiology
 and Immunology). Available from: https://doi.org/10.1007/82 2013 331
- 251 2. Chin CS, Sorenson J, Harris JB, Robins WP, Charles RC, Jean-Charles RR, et al. The Origin
 252 of the Haitian Cholera Outbreak Strain. N Engl J Med. 2011 Jan 6;364(1):33–42.
- 3. Frerichs RR, Keim PS, Barrais R, Piarroux R. Nepalese origin of cholera epidemic in Haiti.
 Clin Microbiol Infect. 2012 Jun;18(6):E158–63.
- 4. Farmer P, Almazor CP, Bahnsen ET, Barry D, Bazile J, Bloom BR, et al. Meeting Cholera's
 Challenge to Haiti and the World: A Joint Statement on Cholera Prevention and Care. Small
 PLC, editor. PLoS Negl Trop Dis. 2011 May 31;5(5):e1145.
- 5. Piarroux R, Frerichs RR. Cholera and blame in Haiti. Lancet Infect Dis. 2015
 Dec;15(12):1380–1.
- 260 6. Jenson D, Szabo V. Cholera in Haiti and Other Caribbean Regions, 19th Century. Emerg
 261 Infect Dis. 2011 Nov;17(11):2130–5.
- 262 7. Cholera Haiti. Geneva, Switzerland: World Health Organization; 2022.
- 8. National plan for the elimination of cholera in Haiti; 2013-2022. Port au Prince, Haiti:
 Republic of Haiti Ministry of Public Health and Population National Directorate for Water
 Supply and Sanitation; 2013.
- 266 9. Santé WHO= O mondiale de la. Cholera 2019 Choléra 2019. Vol. 95, Weekly
 267 Epidemiological Record = Relevé épidémiologique hebdomadaire. World Health
 268 Organization = Organisation mondiale de la Santé; 2020. p. 441–8.
- 10. 4 février 2019 4 février 2022 trois (3) ans SANS CHOLÉRA en Haïti [Internet]. Le
 Ministère de la Communication Republique d'Haiti. 2022. Available from:
 https://www.communication.gouv.ht/2022/02/4-fevrier-2019-4-fevrier-2022-trois-3-ans-
- 271 https://www.communication.gouv.nt/2022/02/4-fevrier-2019-4-fevrier-2022-trois-3-ans 272 sans-cholera-en-haiti/
- 273 11. Epidemiological Update Cholera January 31, 2023 [Internet]. Pan American Health
 274 Organization / World Health Organization; 2023 Jan. Available from:
 275 https://www.paho.org/en/documents/epidemiological-update-cholera-31-january-2023
- Rubin DHF, Zingl FG, Leitner DR, Ternier R, Compere V, Marseille S, et al. Reemergence
 of Cholera in Haiti. N Engl J Med. 2022 Nov 30;NEJMc2213908.

- 278 13. Mavian CN, Tagliamonte MS, Alam MT, Sakib SN, Cash MN, Riva A, et al. Re-emergence
- of cholera in Haiti linked to environmental *V. cholerae* O1 Ogawa strains [Internet].
- Infectious Diseases (except HIV/AIDS); 2022 Nov [cited 2022 Dec 19]. Available from:
 http://medrxiv.org/lookup/doi/10.1101/2022.11.21.22282526
- 282 14. Daniels JP. Cholera surges in Haiti. The Lancet. 2022 Dec;400(10367):1913.
- 283 15. Taylor L. Haiti's hospitals plan to close amid fuel shortages. BMJ. 2022 Oct 3;o2379.
- 16. Rebaudet S, Bulit G, Gaudart J, Michel E, Gazin P, Evers C, et al. The case-area targeted
 rapid response strategy to control cholera in Haiti: a four-year implementation study. Gurley
 E, editor. PLoS Negl Trop Dis. 2019 Apr 16;13(4):e0007263.
- 17. Rebaudet S, Dély P, Boncy J, Henrys JH, Piarroux R. Toward Cholera Elimination, Haiti.
 Emerg Infect Dis. 2021 Nov;27(11):2932–6.
- 18. Severe K, Alcenat N, Rouzier V. Resurgence of Cholera in Haiti amidst Humanitarian
 Crises. N Engl J Med. 2022 Nov 30;NEJMc2213782.
- 19. Kauffman RC, Bhuiyan TR, Nakajima R, Mayo-Smith LM, Rashu R, Hoq MR, et al. SingleCell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of
 Cross-Reactive Memory B Cells. mBio. 2016 Dec 20;7(6):e02021-16.
- 20. Aktar A, Rahman MA, Afrin S, Akter A, Uddin T, Yasmin T, et al. Plasma and memory B
 cell responses targeting O-specific polysaccharide (OSP) are associated with protection
 against Vibrio cholerae O1 infection among household contacts of cholera patients in
 Bangladesh. Small PLC, editor. PLoS Negl Trop Dis. 2018 Apr 23;12(4):e0006399.
- 21. Azman AS, Lessler J, Luquero FJ, Bhuiyan TR, Khan AI, Chowdhury F, et al. Estimating
 cholera incidence with cross-sectional serology. Sci Transl Med. 2019 Feb
 20;11(480):eaau6242.
- 301 22. Iyer AS, Harris JB. Correlates of Protection for Cholera. J Infect Dis. 2021 Dec
 302 20;224(Supplement_7):S732–7.
- 303 23. Bi Q, Ferreras E, Pezzoli L, Legros D, Ivers LC, Date K, et al. Protection against cholera
 304 from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis. Lancet
 305 Infect Dis. 2017 Oct;17(10):1080–8.
- 24. Qadri F, Wierzba TF, Ali M, Chowdhury F, Khan AI, Saha A, et al. Efficacy of a SingleDose, Inactivated Oral Cholera Vaccine in Bangladesh. N Engl J Med. 2016 May
 5;374(18):1723–32.
- 309 25. Barzilay EJ, Schaad N, Magloire R, Mung KS, Boncy J, Dahourou GA, et al. Cholera
 310 Surveillance during the Haiti Epidemic The First 2 Years. N Engl J Med. 2013 Feb
 311 14;368(7):599–609.

- 312 26. Haiti Cholera figures; As of 31 January 2019. [Internet]. United Nations Office for the
 313 Coordination of Humanitarian Affairs.; 2019. Available from:
- https://www.humanitarianresponse.info/sites/www.humanitarianresponse.info/files/documen
 ts/files/ocha-hti-cholera-figures-20190131 en.pdf
- 27. Ivers LC, Teng JE, Lascher J, Raymond M, Weigel J, Victor N, et al. Use of Oral Cholera
 Vaccine in Haiti: A Rural Demonstration Project. Am J Trop Med Hyg. 2013 Oct
 9;89(4):617–24.
- 28. Rouzier V, Severe K, Juste MAJ, Peck M, Perodin C, Severe P, et al. Cholera Vaccination in
 Urban Haiti. Am J Trop Med Hyg. 2013 Oct 9;89(4):671–81.
- 321 29. Haiti's Ministry of Health organizing a vaccination campaign against cholera in areas
 322 affected by Hurricane Matthew, supported by PAHO-WHO, UNICEF and other partners.
 323 Pan American Health Organization; 2016.
- 30. Iyer AS, Azman AS, Bouhenia M, Deng LO, Anderson CP, Graves M, et al. Dried Blood
 Spots for Measuring Vibrio cholerae-specific Immune Responses. Kosek M, editor. PLoS
 Negl Trop Dis. 2018 Jan 29;12(1):e0006196.
- 31. Arnold BF, Martin DL, Juma J, Mkocha H, Ochieng JB, Cooley GM, et al. Enteropathogen
 antibody dynamics and force of infection among children in low-resource settings. eLife.
 2019 Aug 19;8:e45594.
- 32. Harris JB, LaRocque RC, Chowdhury F, Khan AI, Logvinenko T, Faruque ASG, et al.
 Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with
 cholera in Bangladesh. PLoS Negl Trop Dis. 2008 Apr 9;2(4):e221.
- 33. Haney DJ, Lock MD, Simon JK, Harris J, Gurwith M. Antibody-Based Correlates of
 Protection Against Cholera Analysis of a Challenge Study in a Cholera-Naïve Population.
 Clin Vaccine Immunol CVI. 2017 May 31;24(8):e00098-17, CVI.00098-17.
- 336 34. Klarman M, Schon J, Cajusma Y, Maples S, Beau de Rochars VEM, Baril C, et al.
 337 Opportunities to catalyse improved healthcare access in pluralistic systems: a cross-sectional
 338 study in Haiti. BMJ Open. 2021 Nov;11(11):e047367.
- 339

- 341
- 342